二尖瓣置换术中保留腱索的手术细节与临床结局
单中心2015-2024年320例二尖瓣置换患者中,244例(76.3%)保留腱索、76例(23.7%)未保留,经逆概率加权调整后两组四年生存率相似(79.0% vs 75.3%,p=0.31),左心室射血分数与舒张末径变化亦无差异。亚组分析中黏液样病变保留腱索与生存改善相关(aHR 0.23 [0.09-0.59],p=0.002),但病因交互检验无统计学意义(Wald p=0.44)。
要点
- 调整后保留腱索未改善整体生存(aHR 0.67 [0.33-1.35],p=0.26)。
- 左心室射血分数与舒张末径变化两组相似。
- 黏液样病变亚组生存获益,但病因交互检验无意义。
核心结论
- 当代二尖瓣置换队列中,调整后保留腱索与总体生存及早期左心室功能无差异。
- 未发现二尖瓣病变病因修饰保留腱索与结局的关联。
研究设计与样本
- 单中心2015-2024年连续二尖瓣置换患者320例,分为保留腱索组244例(76.3%)与未保留组76例(23.7%)。
- 采用逆概率治疗加权平衡基线差异,主要结局为生存,次要结局为术前术后超声左心室射血分数与舒张末径变化。
- 按二尖瓣病变病因进行亚组分析。
主要发现
- 调整后Kaplan-Meier分析显示保留腱索与未保留组术后四年生存率相似(79.0% vs 75.3%,p=0.31)。
- 多变量Cox回归调整同期三尖瓣手术与人工瓣膜类型后,保留腱索与生存无显著关联(aHR 0.67 [0.33-1.35],p=0.26)。
- 左心室射血分数百分比变化(-1.2% vs -1.5%,p=0.94)与舒张末径百分比变化(-13.5% vs -6.5%,p=0.12)两组相似。
- 调整后亚组分析中,黏液样病变保留腱索与生存改善相关(aHR 0.23 [0.09-0.59],p=0.002),风湿性病变无显著关联(aHR 0.55 [0.20-1.52],p=0.25)。
- 病因交互作用检验无统计学意义(Wald p=0.44)。
临床怎么用
- 当代二尖瓣置换中保留腱索不应仅以改善总体生存或早期左心室功能为目的常规强制实施。
- 对黏液样病变患者保留腱索可能带来生存获益,但需注意交互检验无统计学意义,证据尚不确凿。
局限性
- 单中心回顾性队列研究,样本量320例。
- 亚组分析中病因交互作用检验无统计学意义(Wald p=0.44),亚组结果应谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chordal preservation in mitral valve replacement (MVR) has been historically associated with favorable postoperative left ventricular remodeling. We evaluated the outcomes of chordal preservation in a contemporary MVR cohort. METHODS: Consecutive MVR patients at a single institution (2015-2024) were divided into chordal preservation and non-preservation groups. Baseline differences were balanced by inverse probability of treatment weighting. Primary outcome was survival. Secondary outcomes included change in left ventricular ejection fraction and end-diastolic diameter between pre- and postoperative echocardiography. Subgroup analyses by mitral valve disease etiology were performed. RESULTS: Of 320 patients, 244 (76.3%) underwent chordal preservation and 76 (23.7%) did not. Adjusted Kaplan-Meier analysis demonstrated similar postoperative four-year survival between chordal preservation and non-preservation patients (79.0% vs. 75.3%, p=0.31), confirmed by multivariable Cox regression adjusting for concomitant tricuspid surgery and prosthesis type (aHR 0.67 [0.33-1.35], p=0.26). Percent change in left ventricular ejection fraction (-1.2% vs. -1.5%, p=0.94) and end-diastolic diameter (-13.5% vs. -6.5%, p=0.12) were similar. In adjusted subgroup analyses, chordal preservation was associated with improved survival in myxomatous disease (aHR 0.23 [0.09-0.59], p=0.002) but not rheumatic disease (aHR 0.55 [0.20-1.52], p=0.25); however, formal interaction analysis showed no evidence that the effect of preservation differed by etiology (Wald p=0.44). CONCLUSIONS: After adjustment, chordal preservation was not associated with differences in overall survival or early left ventricular function in contemporary MVR. We found no evidence that mitral valve disease etiology modifies this association.
引用
- Lao J, Feng I, Inan B, et al. Operative Details and Clinical Outcomes of Chordal Preservation in Mitral Valve Replacement Surgery. Ann Thorac Surg. 2026. PMID: 42849599. doi:10.1016/j.athoracsur.2026.09.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。